Form 4: Clover Health CEO Schedules Significant Stock Sales Under 10b5-1 Plan

Conrad Wai, CEO of Counterpart Health, a subsidiary of Clover Health Investments, Corp., has scheduled the sale of over 200,000 Class A Common Stock shares in July 2025 under a pre-arranged trading plan.

Summary

• Conrad Wai, CEO of Counterpart Health and an officer of Clover Health Investments, Corp. (CLOV), has reported planned sales of Class A Common Stock.
• On July 22, 2025, 118,600 shares are scheduled to be sold at a weighted average price of $3.29 per share, with prices ranging from $3.25 to $3.37.
• On July 23, 2025, an additional 91,197 shares are scheduled to be sold at a weighted average price of $3.32 per share, with prices ranging from $3.25 to $3.40.
• These sales are being conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Wai on March 3, 2025.
• Following these transactions, Mr. Wai's beneficial ownership will include 1,403,701 shares held indirectly by trust and 1,699,767 shares held directly.

Sentiment

Score: 4

Explanation: The planned sale of a substantial number of shares by a key executive, even under a 10b5-1 plan, generally indicates a lack of strong conviction for significant future stock price appreciation, leading to a moderately negative sentiment.

Negatives

• A key executive, the CEO of a subsidiary, is planning to reduce their direct and indirect holdings in the company, which can be interpreted as a lack of strong conviction in significant future stock price appreciation.
• The planned sale of over 200,000 shares represents a notable divestment by an insider.

Risks

• Insider selling, even under a pre-arranged plan, can negatively impact investor sentiment and potentially lead to downward pressure on the stock price.
• The planned reduction in a key executive's stake might signal internal concerns about the company's near-term prospects or valuation.

Industry Context

This filing pertains to an individual executive's stock transactions and does not directly provide broader industry context or trends. However, insider selling in the healthcare technology sector is often scrutinized for signals regarding company performance or market outlook.

Stakeholder Impact

• Shareholders may interpret the planned insider selling as a negative signal, potentially leading to decreased confidence and selling pressure on the stock.

Key Dates

Recommendation

While the sales are pre-planned under a 10b5-1 plan, the decision by a key executive to divest a significant portion of their holdings suggests a tempered outlook on the stock's future appreciation. This action, while not indicative of immediate distress, warrants caution for investors, suggesting a 'hold' position rather than a 'buy' given the potential for negative sentiment.

Keywords

Clover Health Investments, CLOV, Conrad Wai, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Beneficial Ownership, Healthcare Technology